"Never doubt that a small group of thoughtful, committed citizens can change the world. Indeed, it is the only thing that ever has."

Margaret Mead

Original article
peer-reviewed

Congestive Heart Failure Hospitalizations and Cannabis Use Disorder (2010–2014): National Trends and Outcomes



Abstract

Background and objectives: Prior studies have suggested that cannabis use is an independent risk factor for heart failure. With increasing recreational use of cannabis and decriminalization policies, cannabis use is expected to add to the burden of heart failure, but there is still limited data. Therefore, we utilized the Nationwide Inpatient Sample (NIS) database (2010-2014) to study the national trends and outcomes among cannabis users admitted for congestive heart failure (CHF).

Methods: We queried the NIS database and identified CHF as the primary diagnosis with a co-diagnosis of cannabis use disorder (CUD). Trends were analyzed with the linear-by-linear association.

Results: Total CHF admissions (N = 4,596,024) with comorbid CUD (N = 23,358 (0.5%)) were identified. An increasing prevalence trend from 0.4% to 0.7% (P= 0.001) was seen. CUD patients had a mean age of 49.78 years, 79% were males, 55.4% were African Americans, and 73.6% earn ≤ 50th percentile median household income of the patient’s ZIP code. Inpatient deaths (1.1% vs. 3.1%) were lower (P<0.001), and mean length of stay (LOS) was shorter among cannabis users compared to non-users (P=0.001). The mean LOS and total hospitalization costs demonstrated an increasing trend (Ptrend = 0.001 and Ptrend < 0.001) respectively. Alcohol abuse and depression were more prevalent among CUD compared to non-CUD patients.

Conclusion: CUD was associated with reduced inpatient deaths, but the prevalence of CUD and hospital charges is on the rise in the CHF inpatient population in addition to shorter mean LOS. Notwithstanding, these above findings prompt further research into its underlying mechanisms along with a probable causal relationship between cannabis and heart failure.

Introduction

The past decade has witnessed unprecedented legalization and decriminalization of cannabis use across many states in the United States [1]. However, cannabis still maintains its status as a strictly prohibited drug at the federal level [1]. Marijuana is currently the most commonly used recreational drug in the United States, with >22 million users per month [2]. As of December 2018, marijuana was legal for medicinal use in thirty-three states and the District of Columbia (DC), while ten states and DC have enacted policies enabling recreational marijuana use [3].

Heart failure constitutes a significant public health issue, and its estimated prevalence is >5.7 million in the United States (US) [4]. Heart failure also constitutes a huge strain on the health care system, responsible for health care costs greater than $39 billion annually in the US [4]. The lifetime risk of developing heart failure is estimated to be 20% [4]. Thus, the consensus from a few published case reports and studies is that cannabis use may be associated with the development of left ventricular dysfunction and heart failure [5-8]

However, there is a dearth of systematic studies evaluating outcomes and trends of cannabis use disorder (CUD) in acute heart failure.

Based on limited data on comorbid CUD in heart failure patients, our study used Nationwide Inpatient Sample (NIS) data to determine the trends of demographic factors, in-hospital outcomes, and comorbidities for congestive heart failure (CHF) hospitalizations and cannabis use. Next, we compared in-hospital outcomes among CUD vs. non-CUD patients admitted for CHF

Materials & Methods

Data source

We used the NIS data in our study and diagnostic information was obtained using the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes, and clinical classification (CCS) codes [9].

Inclusion criteria

We identified 4,596,024 patients with a primary discharge diagnosis of CHF using ICD-9-CM codes of 398.91, 402.01, 402.11, 402.91, 404.01, 404.03, 404.11, 404.13, 404.91, 404.93, 428.0-428.9 and 23,358 patients with co-morbid CUD using ICD-9-CM codes 304.30-304.32, and 305.2.

Variables of interest

To study the demographic trends in patients admitted for CHF with CUD from 2010-2014, we included demographic factors such as age, race, gender, household income, and primary payer status [10]. We compared the baseline demographics and in-hospital outcomes-length of stay (LOS), in-hospital mortality, and total hospital costs) between CUD and non-CUD patients admitted for CHF.

Comorbidities were considered coexisting clinical conditions to CHF. For assessment of comorbidities, the Agency for Healthcare Research and Quality (AHRQ) comorbidity software was used to create binary variables [11], then ICD-9 CM diagnosis codes were used to identify comorbidities. The ICD-9 CM codes used to determine the comorbid conditions are available in the appendices. We also applied discharge weights (DISCWT) to obtain a nationwide representative sample population [10].

Statistical analyses

Statistical analysis was done by SPSS version 25 (IBM, Armonk, NY, US). We used the independent sample t-test and analysis of variance (ANOVA) for measuring continuous data. Pearson’s chi-square test was used for categorical data. Trends were analyzed with the linear-by-linear association tests. A p-value ≤ 0.05 was used to define the statistical significance of the tests. The NIS database did not contain any personally identifiable information. Therefore, an institutional review board (IRB) approval was not needed for this study.

Results

Demographics, inpatient outcomes and trends

The total number of admissions identified with a primary diagnosis of CHF over the five years was N = 4,596,024, and 0.5% (N = 23,358) of these patients had a co-diagnosis of CUD as shown in Table 1 below.

  CHF, N = 4,596,024      
Variable Non-CUD CUD P-Value
N % N %
Total admissions 4,572,666 99.5 23,358 0.5  
Mean age at admission (SD), in years 72.77 (14.43) 49.78 (11.24) <0.001
Sex
Males 2,296,127 50.2 18,448 79.0 <0.001
Females 2,276,092 49.8 4910 21.0
Race
White 2,920,078 68.4 7111 31.9 <0.001
African Americans 831,467 19.5 12,362 55.4
Hispanic 32,090 7.5 1803 8.1
Other 197,758 4.6 1034 4.6
Median household income, in percentile
0–25th 1,481,175 33.1 11,666 51.8 <0.001
26th–50th 1,184,624 26.4 5157 22.9
51st–75th 1,020,324 22.8 3906 17.4
76th–100th 793,574 17.7 1781 7.9
Primary payer
Medicare 344,360 75.5 6505 27.9 <0.001
Medicaid 369,350 8.1 8950 38.5
Private 523,995 11.5 2488 10.7
Self-pay or uninsured 147,146 3.2 4164 17.9
Others 79,127 1.7 1169 5.0  
Comorbidities
Alcohol abuse 126,464 2.8 6075 26.0 <0.001
Depression 4,555,384 10.0 2500 10.7 <0.001
Diabetes, without complications 1,574,996 34.4 5704 24.4 <0.001
Diabetes, with complications 478,489 10.5 3700 7.7 <0.001
Hypertension 3,436,096 75.1 17,276 74.0 <0.001
Metastatic cancer 45,995 1.0 89 0.4 <0.001
Renal failure 188,1371 41.1 7153 30.6 <0.001
Severity of illness
Nil 221 <0.1 0 0.0 0.001
Minor 324,608 7.1 2263 9.7
Moderate 1,680,851 36.8 9154 39.2
Major 2,566,986 56.1 11,941 51.1
Other hospital outcomes
Mean length of stay (SD), in days 5.19 (5.82) 4.62 (4.98) 0.001
Mean total charges in (USD) 40,730 41,642 0.08
In-hospital mortality 140,878 3.1 249 1.1 <0.001

The proportion of total CUD admissions had an increasing trend from 0.4% (N = 3588) in 2010 to 0.7% (N = 6365) in 2014, which represents a 77.4% (Ptrend < 0.001) increase over the five years as shown in Table 2 below.

Variables 2010 2011 2012 2013 2014 Overall Total Ptrend Trend Direction
No Of CUD admissions 3588 3970 4305 5130 6365 23,358    
CUD admissions prevalence (%) 0.4 0.4 0.5 0.6 0.7 0.5 <0.001 Increasing
Age at admission                
Mean age (SD) (in years) 48.08 (11.41) 48.93 (11.22) 50.11 (11.22) 50.25 (10.81) 50.65 (11.38) 49.78 (11.24) <0.001 Increasing
Gender (%)                
Males 81.7 78.9 81.2 78.9 76.0 79 0.001 Decreasing
Females 18.3 21.1 18.8 21.1 24.0 21.0 0.001 Increasing
Race (%)                
Whites 25.7 33.7 27.8 33.9 35.3 31.9 0.466 Increasing
African Americans 64.1 52.8 57.8 53.6 52.1 55.4 0.466 Decreasing
Hispanics 7.4 9.7 8.3 7.8 7.6 8.1 0.466 Increasing
Others 2.8 3.8 6.2 4.7 5.0 4.6 0.466 Increasing
Income level (%)                
0–25th percentile 54.3 49.7 53.2 48.5 53.5 51.8 0.851 Variable
26th–50th percentile 22.7 21.1 21.7 25.4 23.0 22.9 0.851 Variable
51st–75th percentile 16.8 19.6 17.8 17.4 15.9 17.4 0.851 Variable
76th–100th percentile 6.2 9.5 7.3 8.8 7.6 7.9 0.851 Increasing
Insurance (%)                
Medicare 26.3 27.2 28.3 27.9 29.1 27.9 <0.001 Increasing
Medicaid 34.5 35.6 36.8 36.5 45.1 38.4 <0.001 Increasing
Private 13.2 11.5 10.0 10.4 9.4 10.7 <0.001 Decreasing
Self-pay 20.2 19.2 18.6 19.5 14.0 17.9 <0.001 Decreasing
Other 5.7 6.4 6.3 5.7 2.4 5.0 <0.001 Variable
Severity of Illness (%)                
Minor 8.9 8.8 10.9 11.4 8.5 9.7 0.946 Variable
Moderate 39.4 37.5 41.8 39.3 38.3 39.2 0.946 Variable
Major 51.7 53.6 47.3 49.3 53.3 51.1 0.946 Variable
Other hospital outcomes                
In-hospital mortality (%) 0.7 0.8 1.5 1.2 1.0 1.1 0.137 Increasing
Mean total charges in USD 34,776 44,100 41,729 42,451 43,292 41,642 <0.001 Increasing
Mean length of stay (SD) (in days) 4.21 (3.58) 4.61 (4.39) 4.72 (5.30) 4.76 (5.95) 4.66 (4.91) 4.62 (4.98) 0.001 Increasing

The mean age of CUD patients increased significantly from 48.08 ± 11.41 years in 2010 to 49.78 ± 11.24 years (Ptrend < 0.001). Males (79%) constituted most of the cannabis users, but there was a significant declining trend of CUD prevalence from 81.7% in 2010 to 76.0% in 2014 (Ptrend = 0.001). Conversely, CUD prevalence among females increased from 18.3% to 21.0% in the five years (Ptrend = 0.001). More than half of cannabis users were African Americans, followed by Caucasians (31.9%), Hispanics (8.1%), and others (4.6%). CUD prevalence among Whites and Hispanics followed an increasing trend but followed a decreasing trend among African Americans. All race groups showed a non-statistically significant trend (Ptrend = 0.466).

Regarding median household income in percentiles, CUD prevalence among patients below the 25th percentile, 26th to 50th percentile, and 51st to 75th percentile showed a variable trend, while CUD prevalence in the highest percentile demonstrated an increasing trend from 2010 to 2014 (Ptrend = 0.851). Patients below the 25th percentile represented about half of the CUD admissions.

In terms of insurance status, Medicaid was the primary insurance for 38.4% of the total CUD population, while Medicare was the primary payer for 27.9%. Both Medicaid and Medicare payments had an increasing trend (Ptrend < 0.001). Private insurance and self-pay mode of payment followed statistically significant down-trend payments from 13.2% to 9.4% and 20.2% to 14% over the five years (Ptrend < 0.001) respectively.

Cannabis users with major morbidity made up 51.1% of the total CUD population, and there was a non-statistically significant variable trend from January 2010 to December 2014 (Ptrend = 0.946). In-hospital mortality (1.1% vs. 3.1%), was lower, and mean LOS in days were shorter in CUD patients compared to the non-CUD cohort (P < 0.001) and (P = 0.001) respectively. There was a non-statistical difference in total hospital charges between CUD and non-CUD patients (P = 0.08).

In-hospital mortality among CUD patients followed a non-statistically significant trend from 0.7% to 1.1% from 2010 to 2014 (Ptrend < 0.137), but there were a significant trend increase from 2010 to 2014 for both LOS in days (Ptrend = 0.001) and total hospital charges (Ptrend < 0.001).

Comorbidities and trends

Comorbidities of diabetes, hypertension, renal failure, and metastatic cancer were less prevalent among cannabis users as shown in Figure 1 below.

At the same time, alcohol abuse and depression were more prevalent among CUD patients. Alcohol abuse showed a significant decreasing trend from 2010 to 2014 (Ptrend < 0.001) as shown in Table 3 below

Comorbidities 2010 2011 2012 2013 2014 Total P trend Trend Direction
Alcohol abuse 27.1% 26.9% 27.1% 26.1% 24.0% 26.0% <0.001 Decreasing
Depression 10.4% 11.4% 10.1% 10.3% 11.2% 10.7% 0.621 Variable
Diabetes without complications 22.1% 22.4% 26.5% 24.9% 25.2% 24.4% <0.001 Increasing
Diabetes with complications 6.2% 8.1% 6.6% 8.0% 8.6% 7.7% <0.001 Increasing
Hypertension 73.9% 73.4% 74.7% 73.2% 74.5% 74.0% 0.590 Variable
Metastatic Cancer 0.3% 0.4% 0.1% 0.8% 0.3% 0.4% 0.126 Variable
Renal failure 30.6% 30.6% 29.8% 30.4% 31.3% 30.6% 0.412 Stable

Conversely, diabetes, with and without complications significantly increased in a linear trend from 2010 to 2014 (Ptrend < 0.001).

Comorbidities of hypertension (Ptrend = 0.590), depression (Ptrend = 0.621), and metastatic cancer (Ptrend = 0.126) showed a non-significant variable trend. Renal failure was the only comorbidity that showed a stable linear trend. 

Discussion

This study considered demographic factors (age, race, gender, insurance type, household income), the severity of illness, in-hospital mortality, total hospital charges, and LOS in both cannabis users and non-users. Trends of coexisting comorbidities among CHF hospitalizations with CUD was also explored. We reported an overall prevalence of CUD among CHF inpatients as 0.5% and a significant trend of 77.4%. These findings are similar to a recent study by Charilaou et al. that reported an increase in cannabis abuse prevalence in patient populations from 0.5% to 1.3% from 2002 to 2011 [12]. Our observation may be partially explained by the legalization of medical and recreational cannabis in the many U.S. states [13,14], which consecutively led to an increase in the prevalence of cannabis users in the general population, and by extension increased the odds of observing them in admitted patients, including CHF hospitalizations [12].

In another study of cannabis use, Kalla et al. showed that cannabis use was an independent risk predictor of heart failure [8]. Evidence of this association between cannabis use and heart failure is backed by prior human and animal studies [15-18]. Three earlier studies showed that endocannabinoids acting on CB-1 receptors caused decreased myocardial contractility [15-17]. Su et al. also showed that the negative inotropy activity of CB2 agonists, independent of CB1 and CB2 receptors, causes decreased myocardial contractility [18].

Our study showed that cannabis users were predominantly males (79%) with a mean age of 49.8 years. These findings are consistent with findings by Wu and colleagues in a study of the effects of marijuana use on heart failure, which reported a mean age of 50.4 years and predominance of males (78.3%) among marijuana users compared to non-users [19].

Two notable findings of this study are the lower mortality rate (1.1% vs. 3.1%) and reduced LOS (4.62 vs. 5.12 days) among cannabis users compared to non-cannabis users. These results are similar to findings of a previous study that marijuana use was associated with reduced inpatient mortality (odds ratio (OR): 0.197 (0.046-0.083) p = 0.0142) and reduced LOS (4.2 ± 0.1 vs. 4.8 ± 0.2, p = 0.0038) in patients admitted for heart failure [19]. We hypothesized that the lower mortality among CUD patients admitted for heart failure is due to the relatively younger age of this cohort, which makes it possible that the baseline risk of dying in these patients was less than that of non-cannabis users. Another possible explanation for the lower mortality is reduced severity of illiness among cannabis users.

A possible explanation for the reduced mean LOS among cannabis users could be a reduced severity of CHF illness. Notwithstanding these findings require further investigation in the future. This study demonstrated a statistically significant increase in LOS among cannabis users from 2010 to 2014, which we believe caused an increase in hospital charges from ($34,776 to $43,292). Unlike our study which did not show any significant differences in hospital costs between CUD and non-CUD patients, a prior study by Wu et al. [19] demonstrated a significantly lower hospital cost among cannabis users vs. non-users. Although the reason for the above finding is largely speculative, this contrasting finding from previous observation is a significant addition to the body of literature.

Our study revealed essential differences in demographic factors between CUD and non-CUD patients admitted for CHF. Patients hospitalized for CHF with CUD were mostly younger men of African American origin and earned less than the 50th percentile household income. Like our study, it was reported by Nishimura et al. that patients hospitalized for heart failure who had a history of substance abuse were mostly males, and likely to be African American and younger [20].

Alcohol abuse (74% vs. 26%) had a higher prevalence among cannabis users compared to non-CUD. Previous studies of cannabis use in the inpatient population support this finding. Charilaou et al. explored comorbidities associated with cannabis use disorder in inpatients between 2002 to 2011 using the AHRQ comorbidity indicators and reported alcohol abuse as one of the primary comorbid conditions associated with cannabis use [12]. In the same study, approximately 33% of inpatient cannabis users were reported to have a history of alcohol abuse [12]. Similarly, another study that reported alcohol study surveys of marijuana and other illicit drugs revealed that most marijuana users were either binge drinkers or users of other substances [21]. Furthermore, Smit and Crespo studied the nutritional status of adult cannabis users and found out that cannabis users consume higher proportions of alcohol compared to non-users [22]. It is worth mentioning that alcohol abuse is associated with alcoholic cardiomyopathy [23], which is characterized by increased left ventricular mass, left ventricular dilation along with reduced and/or normal ventricular wall thickness [24]

Alcohol abuse as a comorbidity demonstrated a statistically significant decreasing trend from 2010 to 2014. A possible explanation for this phenomenon is the “substitution effect” of alcohol with cannabis use and other illicit drugs by cannabis users [25,26].

Our results showed a higher prevalence of depression among cannabis users vs. non-users (10.7% vs. 10%). Long term use of cannabis has been previously linked with depression [27]. In a prior study of heart failure patients with depression, 15% of these patients were found to have substance abuse problems [28].

This present study has a few limitations that should be considered when interpreting the results. Based on the administrative nature of the NIS database, there is a possibility of coding inaccuracies and classification errors. Secondly, due to the contentious legal and societal status of cannabis use, reporting of cannabis abuse is prone to underreporting bias. Based on the nature of the database, there was unavailability of patient-level information; therefore, adjustment for confounders could not be performed during analysis. Our study, being an observational study, could not assess a temporal relationship between cannabis use and CHF. The level of exposure to cannabis use could not be assessed because of the unavailability of the information in the database, so we were unable to comment on the quantity of cannabis.

Despite these limitations, the NIS database provides an invaluable population-based resource for evaluating national trends. Another strength of this study is obtained from the large sample size of the NIS data, which has enough power to determine differences between CUD and non-CUD CHF populations. Findings from our study also serve as hypotheses and a valuable reference for further research.

Conclusions

Among CUD patients hospitalized for CHF, the trend for the total number of admissions, mean LOS and mean total charges increased significantly over the five-year period of study. In addition, CUD patients had less all-cause in-hospital deaths and shorter hospital stays compared to non-users. Moreover, cannabis users followed a specific demographic profile as they were mostly males, African Americans, and lower-income earners. Further in-depth research is warranted to explore a causal relationship between cannabis use and the development of heart failure


References

  1. Smart R, Pacula RL: Early evidence of the impact of cannabis legalization on cannabis use, cannabis use disorder, and the use of other substances: findings from state policy evaluations. Am J Drug Alcohol Abuse. 2019, 45:644-663. 10.1080/00952990.2019.1669626
  2. Key substance and mental health indicators in the United States: results from the 2015 national survey on drug use and health. (2015). Accessed: May 12, 2020: https://www.samhsa.gov/data/sites/default/files/NSDUH-FFR1-2015/NSDUH-FFR1-2015/NSDUH-FFR1-2015.htm.
  3. Marijuana deep dive: National Conference of State Legislatures. (2018). Accessed: May 12, 2020: http://www.ncsl.org/bookstore/state-legislatures-magazine/marijuana-deep-dive.aspx.
  4. Bui AL, Horwich TB, Fonarow GC: Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011, 8:30-41. 10.1038/nrcardio.2010.165
  5. Kaushik M, Alla VM, Madan R, Arouni AJ, Mohiuddin SM: Recurrent stress cardiomyopathy with variable regional involvement: insights into etiopathogenetic mechanisms. Circulation. 2011, 124:e556-e557. 10.1161/circulationaha.111.059329
  6. Nogi M, Fergusson D, Chiaco JM: Mid-ventricular variant takotsubo cardiomyopathy associated with cannabinoid hyperemesis syndrome: acase report. Hawaii J Med Public Health. 2014, 73:115-118.
  7. Singh A, Agrawal S, Fegley M, Manda Y, Nanda S, Shirani J: Marijuana (cannabis) use is an independent predictor of stress cardiomyopathy in younger men. Circulation. 2016, 134:
  8. Kalla A, Krishnamoorthy PM, Gopalakrishnan A, Figueredo VM: Cannabis use predicts risks of heart failure and cerebrovascular accidents: results from the National Inpatient Sample. J Cardiovasc Med. 2018, 19:480-484. 10.2459/jcm.0000000000000681
  9. Overview of the National (Nationwide) Inpatient Sample (NIS). (2019). Accessed: October 20, 2019: https://www.hcup-us.ahrq.gov/nisoverview.jsp.
  10. NIS description of data elements. (2019). Accessed: October 20, 2019: https://www.hcup-us.ahrq.gov/db/nation/nis/nisdde.jsp.
  11. Elixhauser comorbidity software, version 3.7. (2017). Accessed: October 20, 2019: https://www.hcup-us.ahrq.gov/toolssoftware/comorbidity/comorbidity.jsp.
  12. Charilaou P, Agnihotri K, Garcia P, Badheka A, Frenia D, Yegneswaran B: Trends of cannabis use disorder in the inpatient: 2002 to 2011. Am J Med. 2017, 130:678-687.e7. 10.1016/j.amjmed.2016.12.035
  13. Hoffmann DE, Weber E: Medical marijuana and the law. N Engl J Med. 2010, 362:1453-1457. 10.1056/NEJMp1000695
  14. Cerdá M, Wall M, Keyes KM, Galea S, Hasin D: Medical marijuana laws in 50 states: Investigating the relationship between state legalization of medical marijuana and marijuana use, abuse and dependence. Drug Alcohol Depend. 2012, 120:22-27. 10.1016/j.drugalcdep.2011.06.011
  15. Bátkai S, Pacher P, Osei-Hyiaman D: Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation. 2004, 110:1996-2002. 10.1161/01.Cir.0000143230.23252.D2
  16. Bonz A, Laser M, Küllmer S: Cannabinoids acting on CB1 receptors decrease contractile performance in human atrial muscle. J Cardiovasc Pharm. 2003, 41:657-664. 10.1097/00005344-200304000-00020
  17. Pacher P, Bátkai S, Kunos G: Haemodynamic profile and responsiveness to anandamide of TRPV1 receptor knock-out mice. J Physiol. 2004, 558:647-657. 10.1113/jphysiol.2004.064824
  18. Su Z, Preusser L, Diaz G: Negative inotropic effect of a CB2 agonist A-955840 in isolated rabbit ventricular myocytes is independent of CB1 and CB2 receptors. Curr Drug Saf. 2011, 6:277-284. 10.2174/157488611798918728
  19. Wu L, Narasimhan B, Ho KS, Li P: Marijuana use is associated with better hospital outcome in patients with acute heart failure: a propensity match analysis from national inpatient database. J Card Fail. 2019, 25:S158. 10.1016/j.cardfail.2019.07.452
  20. Nishimura M, Bhatia H, Ma J: The impact of substance abuse on heart failure hospitalizations. Am J Med. 2020, 133:207-213.e1. 10.1016/j.amjmed.2019.07.017
  21. Mohler-Kuo M, Lee JE, Wechsler H: Trends in marijuana and other illicit drug use among college students: results from 4 Harvard School of Public Health College Alcohol Study surveys: 1993-2001. J Am Coll Health. 2003, 52:17-24. 10.1080/07448480309595719
  22. Smit E, Crespo CJ: Dietary intake and nutritional status of U.S. adult marijuana users: results from the Third National Health and Nutrition Examination Survey. Public Health Nutr. 2001, 4:781-786. 10.1079/phn2000114
  23. Lazarević AM, Nakatani S, Nesković AN, et al.: Early changes in left ventricular function in chronic asymptomatic alcoholics: relation to the duration of heavy drinking. J Am Coll Cardiol. 2000, 35:1599-1606. 10.1016/s0735-1097(00)00565-9
  24. Piano MR: Alcoholic cardiomyopathy: incidence, clinical characteristics, and pathophysiology. Chest. 2002, 121:1638-1650. 10.1378/chest.121.5.1638
  25. Lucas P, Reiman A, Earleywine M, et al.: Cannabis as a substitute for alcohol and other drugs: a dispensary-based survey of substitution effect in Canadian medical cannabis patients. Addict Res Theory. 2013, 21:435-442. 10.3109/16066359.2012.733465
  26. Lucas P, Baron EP, Jikomes N: Medical cannabis patterns of use and substitution for opioids & other pharmaceutical drugs, alcohol, tobacco, and illicit substances; results from a cross-sectional survey of authorized patients. Harm Reduct J. 2019, 16:9. 10.1186/s12954-019-0278-6
  27. Reilly D, Didcott P, Swift W, Hall W: Long-term cannabis use: characteristics of users in an Australian rural area. Addiction. 1998, 93:837-846. 10.1046/j.1360-0443.1998.9368375.x
  28. Patel RS, Shrestha S, Saeed H, et al.: Comorbidities and consequences in hospitalized heart failure patients with depression. Cureus. 2018, 10:e3193. 10.7759/cureus.3193

Appendices

 

 

Alcohol abuse 305.00–305.03, 303.00–303.93, 291.9, 291.89, 291.81,291.8, 291.5, 291.0–291.3
Depression 311, 309.1, 309.0, 301.12, 300.4.
Diabetes without complications 648.00–648.04, 250.00–250.33, 249.00–249.31.
Diabetes with complications 775.1, 250.40–250.93, 249.40–249.91.
Hypertension 642.70–642.94,642.10–642.24, 642.00–642.04, 437.2, 402.00–405.99, 401.0, 401.1, 401.9.
Metastatic cancer 199.0–199.2, 198.0–198.89, 197.0–197.8, 196.0–196.9
Renal failure 586, 585.9, 585.6, 585.5, 585.4, 585.3, 404.93, 404.92, 404.13, 404.12, 404.03, 403.01, 404.02, 403.91, V56.8, V56.0-V56.32, V45.12, V45.1, V42.0.
Original article
peer-reviewed

Congestive Heart Failure Hospitalizations and Cannabis Use Disorder (2010–2014): National Trends and Outcomes


Author Information

Temitope Ajibawo Corresponding Author

Internal Medicine, Brookdale University Hospital Medical Center, New York City, USA

Uvie Ajibawo-Aganbi

Health Sciences, Essen Health Care, New York City, USA

Farla Jean-Louis

Internal Medicine, Brookdale University Hospital Medical Center, New York City, USA

Rikinkumar S. Patel

Psychiatry, Griffin Memorial Hospital, Norman, USA


Ethics Statement and Conflict of Interest Disclosures

Human subjects: Consent was obtained by all participants in this study. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Acknowledgements

Some of the results in this manuscript were presented at the American College of Cardiology Scientific Meeting in March 2020


Original article
peer-reviewed

Congestive Heart Failure Hospitalizations and Cannabis Use Disorder (2010–2014): National Trends and Outcomes


Figures etc.

SIQ
8.3
RATED BY 4 READERS
CONTRIBUTE RATING

Scholary Impact Quotient™ (SIQ™) is our unique post-publication peer review rating process. Learn more here.